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Thrombotic microangiopathies (TMAs) include a heterogeneous group of diseases
characterized by abnormalities in the vessel walls of arterioles and capillaries resulting
in microvascular thrombosis that typically presents with a microangiopathic hemolytic
anemia (MAHA) and severe thrombocytopenia. We describe here the case of an
82-year-old woman, who came to our attention for a clinical condition consistent
with thrombotic microangiopathy. Even if initially highly suggestive for a thrombotic
thrombocytopenic purpura (TTP), the elevated ADAMTS13 activity together with
the alteration of the main coagulation parameters (D-dimer elevation, fibrinogen
consumption, slightly prolonged prothrombin time), induced us to consider several other
diseases in the differential diagnostic process. The case evolved toward a suspected
overlapped secondary hemophagocytic syndrome, though the hyperferritinemia was
finally interpreted within the frame of a cytokine storm. After a complex diagnostic
workup, the clinical and biochemical parameters guided us toward the diagnosis of a
cancer-related microangiopathic hemolytic anemia (CR-MAHA) secondary to a relapsing
breast cancer with multiple metastatic localizations. Prednisone 1 mg/kg body weight
was started, and several units of fresh frozen plasma were infused, obtaining a good
control of the hemolysis. No specific oncological therapies were, however, possible,
due to the older age and the critically compromised general condition of the patient;
therefore, after clinical stabilization, the patient was discharged for treatment in a palliative
care Hospital.
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INTRODUCTION
Cancer-related microangiopathic hemolytic anemia (CR-MAHA) is a rare pathologic condition
and often represents a very challenging enigma for the physician at the frontline while facing a
critically ill patient. A broad and fast differential diagnostic process is mandatory to achieve the
correct diagnosis for the most appropriate and potentially successful treatment.
The present case prompted us to review the pathophysiology of thrombotic microangiopathies
and the most recent literature on this multifaceted cluster of diseases (1, 2). In describing
this case, we have an intent of highlighting how crucial it is to dedicate extreme attention to
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the several coagulative and hemachrome parameters for the
achievement of a correct diagnosis of such complex pathologies.
Written informed consent was obtained from the patient for
the publication of this case report.
CASE DESCRIPTION
An 82-year-old woman was referred in December 2019 to our
University Hospital Internal Medicine Unit with a diagnosis
of thrombotic thrombocytopenic purpura, from a nearby
community hospital where she had been admitted few days
before for an episode of mild epistaxis.
No neurological or major hemorrhagic/thrombotic events
were reported. From collection of her clinical history emerged a
type II diabetes mellitus treated with metformin and a history of
ductal infiltrating breast cancer. The breast carcinoma had been
diagnosed in 2006 and firstly treated with quadrantectomy and
radiotherapy (QUART) and tamoxifen and, after documented
relapse in April 2019, with radical mastectomy and axillary lymph
nodes dissection after which she restarted hormone therapy with
anastrazole. The most recent follow-up tests were negative for
disease relapse. As shown in Table 1, when she was admitted her
blood tests showed a mild normochromic normocytic anemia
(Hb 9.3 g/dL) with increased reticulocyte count (325,000 per
µl), and a severe thrombocytopenia (platelet count 32,000 per
µl); lactate dehydrogenase (LDH) was increased (1200 U/L) as
it was total bilirubin (2.5 mg/dL). Coagulation tests highlighted
a slightly prolonged prothrombin time (INR 1.4) with a normal
activated partial thromboplastin time and a severely reduced
plasma concentration of fibrinogen (0.5 g/L) and markedly
elevated plasma concentrations of D-dimer (7000 U/L). Direct
and indirect antiglobulin tests were negative. Renal function
indexes and serum electrolytes concentrations were within the
normal range. A peripheral blood smear showed the presence of
an elevated number of schistocytes (about 20%).
Given the diagnosis of thrombotic thrombocytopenic purpura
hypothesized the day prior to referral to our Internal Medicine
Unit, the patient had been infused with 800 cc of fresh frozen
plasma (FFP).
Right after admission to our Internal Medicine Unit, a sample
for ADAMTS13 activity detection was obtained, whose results
came to our attention few hours after admission and showed a
normal activity (104%).
Even if PLASMIC score, that is, a score that
predicts ADAMTS13 deficiency, in suspected thrombotic
thrombocytopenic purpura (TTP) with high discrimination was
high-intermediate, several aspects did not fit with a presumptive
Abbreviations: MAHA, microangiopathic hemolytic anemia; TTP, thrombotic
thrombocytopenic; ADAMTS13, a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13; QUART, quadrandectomy and
radiotherapy; DIC, disseminated intravascular coagulation; PT, prothrombin
time; aPTT, activated partial thromboplastin time; INR, international normalized
ratio; MCV, mean corpuscular volume; vWF, von Willebrand factor; FFP,
fresh frozen plasma; PEX, plasma exchange; PNH, paroxysmal nocturnal
hemoglobinuria; GPI, glycosylphosphatidylinositol; NK, natural killer; PET,
positron emission tomography; FDG, fludeoxyglucose; US, ultrasonography; CT,
computed tomography; CD, cluster of differentiation; LDH, lactate dehydrogenase.
TABLE 1 | Biochemical parameters at the time of admission and dismission from
the Internal Medicine Unit.
Biochemical parameters At admission At dismission
Hemoglobin (g/dl) 9.3 11.3
Mean corpuscular volume (fl) 96 94
Platelets count (per µl) 32,000 118,000
Reticulocyte count (per µl) 325,000 –
Total bilirubin (µmol/liter) 80 16
LDH (U/liter) 1200 872
Creatinine (µmol/liter) 96.8 57.2
Aptoglobin (g/liter) <0.08 –
D-dimer (ng/ml) 800 –
INR 1.42 1.18
aPTT 1.07 1.03
Fibrinogen (g/liter) 0.5 1.57
ADAMTS13 activity (%) 104 101
Direct Coombs test Negative –
Indirect Coombs test Negative –
Blood smear for schistocytes count 20% –
diagnosis of TTP, which was therefore put into doubt. In fact, the
markedly reduced fibrinogen and the elevated plasma D-dimer
concentrations, together with the normal ADAMTS13 activity,
even if taking into account that the patient had undergone FFP
infusion before testing are not typical of TTP. Plasma exchange
(PEX) was, therefore, not performed, but oral therapy with
prednisone 1 mg/kg body weight was started.
Considering also, in differential diagnosis, the hypothesis of
a subacute disseminated intravascular coagulation (DIC), even
if not fulfiling all the criteria, FFP infusion at low dosage (10
mL/kg/day) was started. Fresh frozen plasma was performed for
four consecutive days and then, because of the normalization
of PT-INR and aPTT with persistently reduced fibrinogen levels
(<1 g/L), fibrinogen infusions were started and maintained for 1
week and eventually stopped, given the absence of either major
or minor bleeding events.
To make a correct differential diagnosis of Coombs negative
hemolytic anemias, other diagnostic hypotheses such as sepsis,
endocarditis, and rheumatic diseases (in primis antiphospholipid
antibody syndrome and systemic lupus erythematosus),
paroxysmal nocturnal hemoglobinuria and folate/vitamin B12
deficiency needed to be excluded. Other primary thrombotic
microangiopathies were not clinically probable, given the
advanced age of the patient, the absence of prodromal diarrhea,
and the normal renal function.
ADAMTS13 activity was subsequently repeated after 1 week,
and it was confirmed to be normal. Also, ADAMTS13 inhibitors
resulted not detectable.
Remarkably, elevated serum ferritin concentrations were
observed (2900 µg/L) and therefore, given the presence of
persistently reduced fibrinogen levels, elevated natural killer
(NK) cells count (>1000 per µl, even if it is clearly not the
right test to demonstrate an altered NK cells function), a bone
marrow biopsy was performed showing a certain grade of
hemophagocytic phenomenon.
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FIGURE 1 | PET scanning with 18-FDG: (A) Image showing diffuse hypermetabolism located at the spinal column; (B) Hepatic lesion of about 1 cm diameter; and
(C,D) Iliac lesion that underwent to CT-guided needle-biopsy.
Even if neoplastic markers, including Ca-15.3, were normal,
concerns arose for the presence of a diffuse relapse of
breast carcinoma, and therefore scar and bilateral axillary
ultrasonography, along with contralateral mammography, were
performed, all of which were negative for neoplastic localizations.
A PET/CT scan was also performed, which showed instead a
diffuse fludeoxyglucose hypercaptation in almost all vertebral
bodies together with other multiple focal bone lesions, and a
unique hepatic lesion of about 1 cm diameter (Figure 1).
The hepatic lesion was too small to possibly perform a US-
guided biopsy; therefore, with the support of our interventional
radiologist, we decided to perform a CT-guided needle biopsy of
the left iliac crest (Figures 1C,D), which resulted positive for the
presence of neoplastic dedifferentiated cells expressing keratins
8-18-19 and GATA-3 at immunohistochemistry, compatible with
metastatic breast carcinoma localizations (Figure 2).
The global performance status of the patient progressively
and rapidly declined during the period of hospitalization,
precluding the possibility of specific oncological therapies;
hence, the patient was lastly dismissed to another hospital
for palliative care, maintaining low dose of oral prednisone
therapy (Table 1).
DIFFERENTIAL DIAGNOSIS
When approaching thrombotic microangiopathy (TMA)
syndromes, terminology is a key element to understand the
entire diagnostic process. Microangiopathic hemolytic anemia
(MAHA) is a descriptive term for non-immune hemolysis
(Coombs-negative hemolysis) resulting from intravascular red
blood cell fragmentation that produces schistocytes on the
peripheral blood smear where characteristic laboratory data
include increased serum LDH, increased indirect bilirubin, and
low serum haptoglobin (1, 2).
Thrombotic microangiopathies describes a specific pathologic
lesion in which abnormalities in the vessel wall of arterioles
and capillaries lead to microvascular thrombosis. Not all MAHA
are caused by a TMA, but nearly all TMAs cause MAHA and
thrombocytopenia (1, 2).
Thrombotic microangiopathies is a pathologic diagnosis
made by tissue biopsy, typically a kidney biopsy; however, it
is commonly inferred from the observation of MAHA and
thrombocytopenia in the appropriate clinical setting.
Primary TMA syndromes include TTP (hereditary or
acquired), Shiga toxin-mediated haemolytic uremic syndrome
(ST-HUS), drug-induced TMA (DITMA) syndromes,
complement-mediated HUS (hereditary or acquired), and
rare hereditary disorders of vitamin B12 metabolism or factors
involved in hemostasis (1).
As for the case of our patient, the presence of a
microangiopathic hemolytic anemia and thrombocytopenia
is, at a first glance, indicative of TTP.
However, the normal ADAMTS13 activity is a key element
to exclude TTP, in which it is almost always below 10% (3,
4). Complement-mediated hemolytic uremic syndrome (HUS)
typically presents with an impaired renal function, and so does
Shiga-toxin-associated HUS; in the latter case, TMA is usually
preceded by diarrhea, abdominal pain, and fever. No new drugs
had been recently introduced by the patient, so even the diagnosis
of a drug-induced TMA was unlikely.
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FIGURE 2 | Histopathological examination from iliac bone biopsy: (A,B) hematoxylin-eosin staining; (C) cytokeratin-8 immunohistochemistry; and (D) GATA-3
immunohistochemistry.
In megaloblastic anemia, ineffective erythropoiesis mimics
MAHA, because of the elevated indirect bilirubin, elevated LDH,
and reduced aptoglobin concentrations. In such a case, the
increased MCV is the key factor to guide the correct diagnosis.
Thrombocytopenia and leucopenia are also generally present, but
the degree of thrombocytopenia is usually not as severe as in TTP.
Dosage of serum vitamin B12 plus autoantibodies to intrinsic
factor in the case of pernicious anemia and folate concentration
are then confirmatory.
Hemolytic anemia in Evans syndrome and antiphospholipid
antibody syndrome is not due to microangiopathy, and its
pathogenesis is invariably autoimmune then featuring a Coombs-
positive hemolytic anemia.
In the case of paroxysmal nocturnal hemoglobinuria,
in which a Coombs-negative hemolytic anemia is present,
thrombocytopenia is due to a reduced medullary production
in the context of an aplastic anemia rather than a peripheral
consumption; in such a case the diagnosis is confirmed by flow-
cytometry for glycosylphosphatidylinositol (GPI)-linked proteins
is the confirmatory test.
Moreover, in TTP, clot formation is very rarely dependent by
the coagulation cascade, being the clot is almost entirely built of
platelets and the von Willebrand factor (vWF). The prolonged
PT-INR, the reduced fibrinogen, and the elevation of D-dimer
plasma levels are suggestive of DIC, but DIC is not generally
associated with the presence of schistocytes in the peripheral
blood smear (5). Moreover, in this case, the antithrombin-III
(AT-III) levels were normal, making the differential diagnosis
even more challenging.
Taking into consideration all of these biochemical parameters,
together with the diagnosis of metastatic breast cancer relapse,
we think that the diagnosis of cancer-related microangiopathic
hemolytic anemia (CR-MAHA) is the most appropriate to solve
the case.
Finally, some case reports of hemophagocytic syndrome
presenting as thrombotic microangiopathy are reported in
the literature, and the possible overlap even of a secondary
form of hemophagocytic syndrome made really hard the right
interpretation of this aspect (6, 7).
The elevated ferritin levels were interpreted as the
epiphenomenon of a cytokine storm, a very complex life-
threatening systemic inflammatory syndrome involving elevated
blood concentration of cytokines and a hyperactivation of
immune cells triggered by several clinical conditions, such as
monogenic and autoimmune disorders, among which are in-
primis hemophagocytic lympho-histiocytosis (HLH), infectious
diseases (including COVID-19), autoimmune pathologies,
various therapies, and even cancers (8). In the case described
here, the hemophagocytic phenomena observed at the bone
marrow biopsy were very limited, and in the absence of more
specific tests, such as the dosage of soluble CD25 and the
evaluation of NK cells activity, the diagnosis of a secondary HLH
could not be formulated with absolute confidence.
DISCUSSION AND LITERATURE REVIEW
Endothelial dysfunction in cancer is an established event (9),
and CR-MAHA, especially in cases of widespread metastasis
of a malignant tumor, is a rare but well-described condition
(10). Cancer-related microangiopathic hemolytic anemia has
been reported in association with several types of carcinomas as
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observed in a report of 168 cases of CR-MAHA, where gastric
cancer was the most frequent, followed by breast, prostate, and
lung cancer (10, 11). Even if CR-MAHA in breast cancer does
not seem to be associated with a specific histological type, ductal
infiltrating carcinoma is the most commonly reported (10). The
pathophysiology behind MAHA in malignancy is yet not well-
understood, even if it is thought to be rather a paraneoplastic
syndrome than an independent condition co-existing with
cancer disease. Two mechanisms have been proposed: red cell
fragmentation against tumor emboli within blood vessels and an
increased vWF multimers release from bone marrow (the latter
in response to altered angiogenesis and secondary myelofibrosis)
(12). Cancer-related microangiopathic hemolytic anemia must
not be confused with chemotherapy-induced MAHA, which is a
specific form of drug-induced TMA, particularly frequent when
using gemcitabine and mitomycin, and can be both immune and
non-immune mediated.
In a 2011 case of a series of eight breast-cancer associated
TMAs, ADAMTS13 activity was normal or slightly reduced, and
basic coagulation parameters (PT-INR and aPTT) were only
minimally altered, exactly as in the case of our patient (13).
von Willebrand factor levels were elevated, but it is known that
vWF is also an acute phase reactant and that vWF plasma levels
are elevated in case of inflammation and many other physical
stressful conditions.
The most effective treatment in CR-MAHA is cancer-specific
chemotherapy, while PEX is almost useless, and the prognosis
is generally very poor (10). Similarly, treatment of secondary
hemophagocytic syndrome is based on the specific oncologic
treatment, which was unfortunately not possible for our patient
due to a degraded performance status, so the choice was directed
toward an adequate palliative care.
CONCLUSIONS
We presented the case of an 82-year-old woman with
CR-MAHA secondary to a metastatic breast cancer relapse.
The main clinical challenge related to this case was to
collect in a unifying diagnosis the ample and diverse set
of all symptoms and laboratory findings presented by the
patient together with the urgency of a prompt diagnosis
to decide the most appropriate therapy for a critically
ill patient.
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